Clinical Development of Anti-TIGIT Antibodies for Immunotherapy of Cancer.

PURPOSE OF REVIEW

T-cell immunoglobulin and ITIM domain (TIGIT) is a next-generation inhibitory receptor with multiple antibodies under exploration in cancer therapy. Here, we review the available data from the early trials and overview upcoming clinical trials on anti-TIGIT antibodies.

RECENT FINDINGS

There is a promising activity of anti-TIGIT, particularly in combination with anti-PD-1/PD-L1 in non-small cell lung cancer (NSCLC) with already phase 3 trials currently ongoing to confirm these early findings. Numerous anti-TIGIT antibodies are in clinical trials currently, and others are in preclinical development. Therefore, more data are expected in the next few years regarding the efficacy of this new checkpoint inhibitor in multiple solid and hematologic malignancies. However, preliminary data are promising, and anti-TIGIT treatment seems to confer more favorable responses when combined with anti-PD-1/anti-PD-L1 compared to either agent alone.